Nektar Therapeutics (NKTR) Interest Coverage Ratio (2010 - 2026)
Nektar Therapeutics (NKTR) posted quarterly Interest Coverage Ratio of 4.92 for Q1 2026, up 45.08% year-over-year from 3.39 in Q1 2025, and down 73.64% quarter-over-quarter from 2.83 in Q4 2025.
Powered by 
Analysis
Nektar Therapeutics (NKTR) Interest Coverage Ratio (2010 - 2026) Analysis & Trends
Nektar Therapeutics' Interest Coverage Ratio history runs 17 years deep, the most recent figure standing at 4.92 for Q1 2026.
- In Q1 2026, Interest Coverage Ratio rose 45.08% year-over-year to 4.92; the TTM figure through Mar 2026 stood at 4.62 (down 11.32% YoY), while the FY2025 annual figure was 0.16, down 28.2% from the prior year.
- Interest Coverage Ratio for Q1 2026 stood at 4.92, down from 2.83 in the prior quarter.
- The five-year high for Interest Coverage Ratio was 1.41 in Q4 2024, with the low at 21.14 in Q2 2022.
- The 5-year median for Interest Coverage Ratio is 7.29 (2022), against an average of 8.27.
- The sharpest annual moves came in 2024 and 2025: Interest Coverage Ratio surged 128.96% in 2024, then sank 300.39% in 2025.
- Nektar Therapeutics' Interest Coverage Ratio stood at 7.29 in 2022, then jumped by 33.03% to 4.88 in 2023, then soared by 128.96% to 1.41 in 2024, then tumbled by 300.39% to 2.83 in 2025, then sank by 73.64% to 4.92 in 2026.
- Business Quant data shows NKTR's Interest Coverage Ratio at 4.92 in Q1 2026, 2.83 in Q4 2025, and 5.24 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -493.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -21.24 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.18 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2.82 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 1.42 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.08 |
| 10 | Nektar Therapeutics | 2.45 Bn | 1.77 Bn | 3.04 Mn | -5.88 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -5.88 |
| Mar 31, 2026 | -4.92 |
| Dec 31, 2025 | -2.83 |
| Sep 30, 2025 | -5.24 |
| Jun 30, 2025 | -6.72 |
| Mar 31, 2025 | -8.95 |
| Dec 31, 2024 | 1.41 |
| Sep 30, 2024 | -5.71 |
| Jun 30, 2024 | -7.77 |
| Mar 31, 2024 | -6.41 |
| Dec 31, 2023 | -4.88 |
| Sep 30, 2023 | -7.59 |
| Jun 30, 2023 | -8.22 |
| Mar 31, 2023 | -21.03 |
| Dec 31, 2022 | -7.29 |
| Sep 30, 2022 | -7.81 |
| Jun 30, 2022 | -21.14 |
| Mar 31, 2022 | -15.48 |
| Dec 31, 2021 | -13.89 |
| Sep 30, 2021 | -8.87 |